<doc>
  <docmeta id="113hr3631ih">
    <bill congress="113" type="hr" number="3631" version="ih"/>
    <revision size="3313" annotations="0" status="complete" id="4" commit-time="2013-12-09T02:49:34Z" committer="mbohmer" doc="113hr3631ih/4.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H8F9C6CD6537B4471A8CA9A2E74B9A47D" public-private="public">
  <metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 3631 IH: Small Manufacturer Protection Act of 2013</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-12-02</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
    <congress>113th CONGRESS</congress>
    <session>1st Session</session>
    <legis-num>H. R. 3631</legis-num>
    <current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
    <action>
      <action-date date="20131202">December 2, 2013</action-date>
      <action-desc>
        <sponsor name-id="H001060">Mr. Hurt</sponsor> (for himself and <cosponsor name-id="R000582">Mr. Roe of Tennessee</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>
      </action-desc>
    </action>
    <legis-type>A BILL</legis-type>
    <official-title>To authorize the Commissioner of Food and Drugs to waive or reduce certain fees applicable to generic drug facilities where the fees would present a significant barrier to market entry because of limited resources available to such facilities or other circumstances.</official-title>
  </form>
  <legis-body id="H2749320A1C8242E2808CF7FAD2F3EEA3" style="OLC">
    <section id="HA42FBBB86C0D46E6A4243AE4C8BB3182" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>Small Manufacturer Protection Act of 2013</short-title>
        </quote>.</text>
    </section>
    <section id="H4580EA8F8AA54902BFD6A7A168386550">
      <enum>2.</enum>
      <header>Waiver or reduction of certain fees applicable to generic drug facilities</header>
      <subsection id="HEC01A74888C04156907F9BEE2AF3A48D">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744B">Section 744B of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-42">
              <cato:entity-ref entity-type="uscode" value="usc/21/379j–42">
            21 U.S.C. 379j–42</cato:entity-ref>
            </external-xref>)</cato:entity> is amended—</text>
        <paragraph id="H3651D643893C41629F43353F2D9741FB">
          <enum>(1)</enum>
          <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744B/ss:b/p:1/sp:B">subsection (b)(1)(B)</cato:entity-ref>, by inserting <quote>, except as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744B/ss:c/p:3">subsection (c)(3)</cato:entity-ref>,</quote> after <quote>fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744B/ss:a/p:2..4">paragraphs (2) through (4) of subsection (a)</cato:entity-ref> shall</quote>; and</text>
        </paragraph>
        <paragraph id="HFEB16ECD484C4B75AEA09718F1638A3A">
          <enum>(2)</enum>
          <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744B/ss:c">subsection (c)</cato:entity-ref>, by adding at the end the following:</text>
          <quoted-block display-inline="no-display-inline" id="H3A50570CAE32471981B57666195CF3E4" style="OLC">
            <paragraph id="HA701A31FC1C24F8783079A363AE88CC0">
              <enum>(3)</enum>
              <header>Fee waivers</header>
              <subparagraph id="H7F8A6175165E4207BF9FAA5F46E9A120">
                <enum>(A)</enum>
                <header>Standard</header>
                <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall grant to a person that owns a generic drug facility a waiver from or a reduction of one or more fees assessed to that person under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744B/ss:a">subsection (a)</cato:entity-ref> where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds that the assessment of the fee would present a significant barrier to market entry because of limited resources available to such person or other circumstances.</text>
              </subparagraph>
              <subparagraph id="H876262E2C98F495AAD426F7247096CE1">
                <enum>(B)</enum>
                <header>Considerations</header>
                <text display-inline="yes-display-inline">In determining whether to grant a waiver or reduction of a fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744B/ss:c/p:3/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consider only the circumstances and assets of the person involved and any affiliate of the person.</text>
              </subparagraph>
              <subparagraph id="H5D09C3EE35334FEC9882C955448AB131">
                <enum>(C)</enum>
                <header>Written requests</header>
                <text display-inline="yes-display-inline">To qualify for consideration for a waiver or reduction under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744B/ss:c/p:3/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, a person shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a written request for such waiver or reduction not later than 180 days after the fee is due.</text>
              </subparagraph>
              <subparagraph id="HEC9978D4F2B84F43B47EEC15856C49EE">
                <enum>(D)</enum>
                <header>Definition</header>
                <text display-inline="yes-display-inline">In this paragraph, the term <term>person that owns a generic drug facility</term> means a person that owns a facility which is identified or intended to be identified in at least one generic drug submission that is pending or approved to produce one or more finished dosage forms of a human generic drug.</text>
              </subparagraph>
            </paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection>
      <subsection id="H4E8E29E12E1A44E6833E9F719A44FBAC">
        <enum>(b)</enum>
        <header>Applicability</header>
        <text>The amendments made by this section apply with respect to fees authorized to be assessed and collected for any of fiscal years 2014 through 2017.</text>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>